{"schema_version":"secwatch.filing_event.v1","accession":"0001639691-26-000006","form_type":"8-K","ticker":"LIVN","cik":"0001639691","company_name":"LivaNova PLC","filed_at":"2026-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.719183+00:00","generated_at":"2026-05-16T00:20:04.258995+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"LivaNova Q4 revenue $360.9M (+12.1%); FY25 adj. EPS $3.90; guides FY26 rev. growth 6-7%","bullets":["Q4 GAAP EPS $0.56; adjusted EPS $0.86. Full-year revenue $1.39B, +10.7% reported.","Full-year GAAP diluted loss per share $4.45 includes $365.6M SNIA environmental charge.","Full-year adjusted diluted EPS $3.90; adjusted free cash flow $183.3M.","2026 guidance: constant-currency revenue growth 6-7%; adjusted EPS $4.15-$4.25.","CMS increased reimbursement for VNS Therapy DRE procedures effective Jan 1, 2026; FDA approved cloud-based digital health platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001639691-26-000006","json":"https://secwatch.observer/filing/0001639691-26-000006.json","markdown":"https://secwatch.observer/filing/0001639691-26-000006.md","text":"https://secwatch.observer/filing/0001639691-26-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1639691/000163969126000006/0001639691-26-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1639691/000163969126000006/livn-20260225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:20:04.258995+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}